Quick Answer
Climb Bio, Inc. reported Operating Income of -$67.88 million for fiscal year 2025.
Climb Bio, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$67.88M | +17.2% |
| 2024 | -$82.02M | -103.6% |
| 2023 | -$40.27M | +10.8% |
| 2022 | -$45.13M | -26.5% |
| 2021 | -$35.67M | -70.5% |
| 2020 | -$20.93M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$14.89M | -26.9% | -39.5% |
| June 30, 2025 | -$10.68M | +81.1% | +53.6% |
| March 31, 2025 | -$23.02M | -666.0% | -96.2% |
| September 30, 2024 | -$11.73M | -134.6% | +79.2% |
| June 30, 2024 | -$56.37M | -739.6% | -1775.9% |
| March 31, 2024 | -$3.00M | +87.2% | +39.9% |
| September 30, 2023 | -$5.00M | +42.8% | +25.5% |
| June 30, 2023 | -$6.71M | +51.0% | +71.4% |
- Climb Bio, Inc. showed an increase of +17.2% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Climb Bio, Inc.’s operating income has declined by 224.4% (from -$20.93 million to -$67.88 million).
- The most recent figure is from Climb Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: